CVRx is a commercial-stage medical device company. Co.'s proprietary platform technology, Barostim, is designed to utilize the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure (HF) and other cardiovascular diseases. Co.'s product, Barostim, is commercially available neuromodulation device indicated to improve symptoms for patients with HF with reduced Ejection Fraction. Barostim provides Baroreflex Activation Therapy by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate the cardiovascular function. The CVRX stock yearly return is shown above.
The yearly return on the CVRX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CVRX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|